Drug intelligence / Profile preview

CFR64 T

Development stage: Preclinical
Lead developer: Gates Institute
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CFR64 T cells are a type of engineered T cell therapy that express a chimeric Fc receptor CD64 (CFR64). This therapy is designed to enhance antitumor activity by providing a controllable and long-lasting immune response. CFR64 T cells exhibit robust cytotoxicity against cancer cells and show better resistance to T cell exhaustion compared to conventional CAR T cells. They are engineered to work with antibodies like trastuzumab, forming a stable immunological synapse and inducing long-term antitumor effects.

Targets

IgG Fc (Immunoglobulin G Fc region)

Beyond the preview

Go deeper on CFR64 T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CFR64 T.

Explore the full profile